In a report issued on May 5, Brian Skorney from Robert W. Baird maintained a Hold rating on Theravance Biopharma (TBPH – Research Report), with a price target of $8.00. The company's shares closed last Friday at $9.32. According to TipRanks.com, Skorney is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of -7.0% and a 41.6% success rate. Skorney covers the Healthcare sector, focusing on stocks such as Eiger Biopharmaceuticals, Vertex Pharmaceuticals, and Enanta Pharmaceuticals. Currently, the analyst consensus on Theravance Biopharma is a Hold with an average price target of $11.17, which is a 21.7% upside from current levels.
https://www.tipranks.com/news/blurbs/robert-w-baird-sticks-to-their-hold-rating-for-theravance-biopharma-tbph?utm_source=advfn.com&utm_medium=referral